Segall Bryant & Hamill LLC Buys Shares of 56,942 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Segall Bryant & Hamill LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 56,942 shares of the medical equipment provider's stock, valued at approximately $5,558,000. Segall Bryant & Hamill LLC owned about 0.08% of Lantheus at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of LNTH. Janus Henderson Group PLC grew its stake in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC boosted its position in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Lantheus by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after purchasing an additional 30,891 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its stake in shares of Lantheus by 39.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after acquiring an additional 273,838 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity

In related news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Down 1.1%

Lantheus stock opened at $73.60 on Friday. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of 20.91 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a twelve month low of $69.12 and a twelve month high of $122.83. The stock has a 50 day moving average of $79.04 and a two-hundred day moving average of $89.57.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business's revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company earned $1.69 earnings per share. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LNTH shares. B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Truist Financial lowered their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday. Finally, Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.